NCT06277154View on ClinicalTrials.gov

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

February 21, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2027

Conditions
LeiomyosarcomaLiposarcomaSynovial SarcomaAngiosarcomaUndifferentiated Pleomorphic SarcomaEpithelioid SarcomaMalignant Peripheral Nerve Sheath TumorsFibrosarcomaPleomorphic RhabdomyosarcomaEndometrial Stromal SarcomaDesmoplastic Small Round Cell Tumor
Interventions
BIOLOGICAL

MASCT-I

The final products of MASCT-I technology are dendritic cells (DC) and effector T cells.

DRUG

Doxorubicin

Commercially approved for cancer treatment

DRUG

Ifosfamide

Commercially approved for cancer treatment

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors

Lead Sponsor

HRYZ Biotech Co.
All Listed Sponsors
collaborator

Sun Yat-sen University

OTHER

lead

HRYZ Biotech Co.

INDUSTRY

NCT06277154 - MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter